Development of peptide type anti cancer drugs against a novel cell growth factor identified by ourselves

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10585
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Kyoto Pharmaceutical University
• Principal Investigator: Yoshiki Tatsuhiro 京都薬科大学, 薬学部, 教授 (80230704)
• Co-Investigator(Kenkyū-buntansha): 花田 英紀 滋賀医科大学, 医学部, 助教 (40555067) ; 影山 進 滋賀医科大学, 医学部, 講師 (50378452)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: C7orf24 / γ-グルタミルシクロトランスフェラーゼ / 抗がん剤 / ペプチド型阻害剤

Outline of Final Research Achievements

We discovered that the C7orf24 protein is highly expressed in bladder cancers. Later, Oakley et al. reported that C7orf24 exhibits functions that are related to those of γ-glutamylcyclotransferase (GGCT). GGCT is one of the major enzymes that is considered having a critical role in glutathione metabolism and it was demonstrated that GGCT is expressed in a variety of cancer cell lines and human cancer tissues. However, whether the enzymatic activity of GGCT plays a role in cancer cell proliferation or tumor progression remained unclear. In this study, we clarified the mechanism of anti-proliferation in GGCT-knockdown cells and anti-cancer activity by a peptide type GGCT inhibitor named pro-GA.

Free Research Field

泌尿器系の腫瘍に対する新規分子標的薬および腫瘍マーカーの探索